Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the company's clinical outlook and follows a strong rally that began in early December after Immutep signed a landmark licensing deal with Dr Reddy's Laboratories. What…

ByUjjwal MaheshwariFebruary 7, 2026

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

The 50% CGT discount on shares is one of the key mechanisms that helps investors keep as much of their cash as they have earned on their investments. We felt that it was time to write a stand-alone article about this in light of the inflation crisis and how it could lead to investors seeking…

ByNick SundichFebruary 5, 2026

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing Telix, Mesoblast and Neuren. Clearly this is one worth looking into and this was before a capital raising that would be $650m and purportedly fund the company into next decade. What are the Best ASX Life…

ByNick SundichFebruary 5, 2026

Island Pharmaceuticals (ASX:ILA) Raises A$9M as FDA Confirms Galidesivir Pathway: Is This Small-Cap Biotech a Buy?

Island Pharmaceuticals jumps after FDA backs galidesivir pathway Island Pharmaceuticals (ASX: ILA) surged as much as 23% to an intraday high of A$0.48 on Wednesday before settling at A$0.42, after delivering a dual catalyst that has significantly de-risked its lead drug program. The US Food and Drug Administration has confirmed the validity of the company's…

ByUjjwal MaheshwariFebruary 5, 2026

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to A$14.63 from a previous close of A$16.25. The sell-off came after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote on trofinetide, the company's Rett syndrome treatment…

ByUjjwal MaheshwariFebruary 4, 2026

Is it Time to Buy ResMed (ASX:RMD)? It is Crushing the Ozempic Fear Narrative with New Data!

ResMed data shows GLP-1 users use CPAP more Is it time to buy ResMed (ASX: RMD)? Well, the company is having good momentum right now - it delivered another strong quarter, beating analyst expectations on both revenue and earnings. The stock currently trades around A$37.50 on the ASX. But the bigger story for investors is…

ByUjjwal MaheshwariFebruary 2, 2026

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

Telix Pharmaceuticals Shares Slide After Regulatory Setbacks Telix Pharmaceuticals (ASX: TLX) has had a brutal twelve months. Shares have fallen around 63% from their February 2025 all-time high of A$31.97 to current levels near A$11.86. What makes this selloff puzzling is that the company achieved its preliminary FY 2025 revenue guidance of A$1.2 billion (US$804…

ByUjjwal MaheshwariJanuary 29, 2026

What happened to Botanix (ASX:BOT) and why are investors sweating

From A$0.53 to A$0.118 Botanix Shows How Fast Biotech Narratives Turn Botanix (ASX:BOT) is a clear example of how quickly sentiment can shift in Australian biotech. The share price has been highly volatile, reaching highs of A$0.53 before falling to A$0.118 today, even after the launch of Sofdra. For context, Sofdra is Botanix’s FDA approved treatment…

ByCharlie YouldenJanuary 27, 2026

Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?

Some investors may think Compumedics (ASX:CMP) is highly undervalued. It trades at $75m, a level that many clinical-stage medtech or biotech stocks are trading well above...but Compumedics is a commercial-stage company expecting nearly that amount of sales for an entire year. What's the story here? What are the Best ASX stocks to invest in right now? Check…

ByNick SundichJanuary 27, 2026

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Aroa Biosurgery adds new trauma study as profits turn positive Aroa Biosurgery (ASX: ARX) shares have seen increased activity this week, hovering around the A$0.70 level following news that the company announced another major clinical milestone. Results from its MASTRR study have been published in the Journal of Trauma and Injury, marking the 116th…

ByUjjwal MaheshwariJanuary 24, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

Island Pharmaceuticals (ASX:ILA) Raises A$9M as FDA Confirms Galidesivir Pathway: Is This Small-Cap Biotech a Buy?

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Is it Time to Buy ResMed (ASX:RMD)? It is Crushing the Ozempic Fear Narrative with New Data!

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

What happened to Botanix (ASX:BOT) and why are investors sweating

Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here